Unauthorized Use of Content on this Site: The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB)—including, but not limited to, those available through the PAAB Forum, the PAAB website, and any PAAB correspondence—are specifically intended to assist individuals navigating the PAAB preclearance system. Repurposing or reproducing this content, or using it for model training or any related purposes, is strictly prohibited without the express prior written consent of PAAB. This includes, but is not limited to, the use of such materials in automated systems, machine learning models, or artificial intelligence applications.
535 - The manufacturers of a drug would like to provide patients (via HCPs) with a wallet card that alerts the patient to show the card to healthcare professionals to remind them to check for potential drug interactions. This focused bit of information is consistent with Part III. Does this require PAAB review?
-
Patient information that will be distributed by or recommended by a health care professional falls under the PAAB scope of review. The question then becomes whether it is exempt from review. As in Ask PAAB #321, a patient piece generated by the manufacturer or its agent requires PAAB review unless both of the following conditions are met: there is no discussion of drug therapy (by product, class, or category) there is no discussion of drug issues (e.g. adherence to medication, potential implications of product ingredients…etc.) The card discusses the issue of interactions in the context of the drug therapy and therefore requires PAAB review.
